Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy

Marcellin, Patrick; Boyer, Nathalie; Gervais, Anne; Martinot, Michèle; Pouteau, M.; Castelnau, Corinne; Kilani, Afef; Areias, Jorge; Aupérin, Anne; Benhamou, Jean Pierre; Degott, Claude; Erlinger, S

doi:10.7326/0003-4819-127-10-199711150-00003

Cited by 538 publications

(377 citation statements)

References 0 publications

Supporting

Mentioning

348

Contrasting

Unclassified

Order By: Relevance

“…Therapy for chronic hepatitis C has greatly improved over the last decade and is still evolving [3][4][5][6][7][8] . T he introduction of peg ylated for m of interferons and addition of ribavirin have further improved the efficacy of therapy in chronic hepatitis C. Higher sustained virological response (SVR) rates in patients with chronic hepatitis C have been reported with pegylated form of interferons compared with standard interferons both as monotherapy as well as in combination with ribavirin [9][10][11][12][13] .…”

Section: Introductionmentioning

confidence: 99%

Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C

Gupta

Ramakrishna

Lakhtakia³

et al. 2006

WJG

View full text Add to dashboard Cite

AIM:To assess the efficacy of peginterferon alpha 2b at doses of 50 mg weekly and 80 mg weekly (based on body weight) plus ribavirin in HCV genotype 2 and genotype 3 chronic hepatitis C patients. METHODS:During the study period of Jan 2002 to Dec 2003, all patients diagnosed as chronic hepatitis C or HCV related compensated cirrhosis were treated with peginterferon alpha 2b 50 mg S/C weekly (body weight < 60 kg) or 80 mg S/C weekly (body weight > 60 kg) plus ribavirin 800 mg/d for 24 wk. RESULTS:Overall 28 patients, 14 patients in each group (based on body weight) were treated during the period. Out of 28 patients, 75% were genotype 3, 18% were genotype 2 and 7% were genotype 1. The mean dose of peginterferon alpha 2b was 0.91 mg/kg in group 1 and 1.23 mg/kg in group 2 respectively. The end of treatment and sustained virologic response rates were 82% and 78% respectively. Serious adverse effects were seen in 3.5% patients. CONCLUSION:Low dose peginterferon alpha 2b in combination with ribavirin for 24 wk is effective in HCV genotype 2 and 3 chronic hepatitis C patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C

Gupta

Ramakrishna

Lakhtakia³

et al. 2006

WJG

View full text Add to dashboard Cite

show abstract

“…Postignut SVR obično se smatra jednakim sa izlečenjem od infekcije kod više od 99% bolesnika [3,6]. Kada se postigne SVR zaustavlja se progresija HHC kod bolesnika bez ciroze jetre.…”

Section: Uvodunclassified

“…Biohemijska procena podrazumeva normalizaciju aktivnosti transaminaza (ALT), a histološka sa zloupotrebom narkotika i alkohola i dr. Na osnovu faktora, koji pozitivno utiču na efikasnost terapije, moguće je predvideti postizanje SVR. To su: ženski pol, životno doba (<40 god), G2 i G3, niska viremija pre terapije, brzi virusološki odgovor, odsustvo ciroze, steatoze jetre, gojaznosti, komorbiditeta, zloupotrebe alkohola i koinfekcija (HBV, HIV) [2,3,[6][7][8][9][10][11][12][13][14][15]. Ukupna doza primljenog RBV utiče na postizanje SVR i relaps.…”

Section: Uvodunclassified

Savremena terapija hroničnog hepatitisa C: efikasnost i mogućnost predviđanja terapijskog odgovora

Bozic

Bojović

Đonić-Nenezić

et al. 2011

BII

View full text Add to dashboard Cite

1Klinika za infektivne i tropske bolesti Kliničkog centra Srbije, Beograd Uvod. Hepatitis C virus (HCV) je jedan od glavnih uzročnika hroničnog hepatitisa, ciroze jetre i hepatocelularnog karcinoma (HCC). Savremena terapija hroničnog hepatitisa C (HHC) podrazumeva primenu pegilovanog interferona alfa 2a ili 2b (PEG IFN-α2a ili PEG IFN-α2b) i ribavirina (RBV). Cilj rada je da se proceni efikasnost HCV terapije i faktora za predviđanje terapijskog odgovora. Rezultati. U grupi bolesnika sa HHC više je bilo muškaraca (59,3%), starijih od 40 godina (58,2%), sa visokim stepenom bazalne viremije (63%) i sa G1 (67%) HCV. Bridging fibroza i ciroza (F3, F4) su nađene kod 54 (27, 84%) bolesnika. Stabilan virusološki odgovor (SVR) je postignut kod 69,2%, relaps kod 11,9%, a bez odgovora na terapiju je bilo 19,8% bolesnika. Faktori koji su uticali na postizanje SVR bili su: non-1 genotip HCV (OR 5,9; 95% IP: 1,9-18,0), EVR (OR 0,92,; 95% IP: 2,73-35,97) i bolesnici mlađi od 40 godina (OR 3,66; 95% IP: 1,48-9,0). Neuspeh terapije u vidu relapsa zavisio je od visine bazalne viremije (OR 0,37; 95% IP: 0,12-0,97), godina života >40 godina (OR 4,8; 95% IP: 1,35-17,84) i prisustva ciroze (OR 2,1; 95% IP: 1,0-4,7). Kod bolesnika bez odgovora na terapiju faktori predviđanja neuspeha su bili: G1 (OR 3,9; 95% IP: 1,5-10,3), visoka bazalna viremija (OR 3,45; 95% IP: 1,19) i prekid u kontinuitetu primene terapije (OR 4,49; 95% IP: 1,76).Zaključak. Savremena, standardna terapija je bila efikasna kod 127/194 (69,2%) bolesnika sa HCC. Najznačajniji faktori za predviđanje uspeha terapije bili su: genotip HCV, EVR kod G1, životno doba bolesnika, stepen bazalne viremije, prisustvo ciroze i prekid u kontinuitetu terapije.Ključne reči: hronični hepatitis C, efikasnost antivirusne terapije, predviđanje virusološkog odgovora.

show abstract

“…The optimal response to IFN-based therapy is undetectable serum HCV RNA levels 6 months following the end of therapy and is defined as a sustained virological response (SVR). A SVR is associated with clearance of hepatic HCV RNA (Marcellin et al, 1997) and improvement in histological fibrosis (Shiratori et al, 2000). Combination therapy with standard IFN plus ribavirin or pegylated IFN plus ribavirin achieves an overall SVR in 40% and 55% of chronic HCV-infected patients, respectively (Manns et al, 2001;McHutchison et al, 1998).…”

Section: Current Hcv Treatment Modalitiesmentioning

confidence: 99%

Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus

Gowans

2004

Journal of Clinical Virology

View full text Add to dashboard Cite

Although hepatitis C virus (HCV) is classified in the Hepacivirus genus in the family Flaviviridae, it is unlike most of the other members of this family due to its propensity to cause persistent infections. This persistent infection eventually results in chronic liver disease, cirrhosis and hepatocellular carcinoma in a proportion of infected individuals. It has been difficult to examine correlates of clearance or persistence because most acute phase HCV infections are subclinical or result in symptoms which are non-specific; consequently, acute infections are not generally recognised and patients often present many years later with persistent infection and accompanying chronic liver disease. Nevertheless, seminal studies, performed during the acute phase, have identified a number of factors which are likely to influence the outcome of infection, although it is possible that the mechanism is multifactorial. One of these factors is impairment of dendritic cell function by a mechanism resulting from expression of an HCV protein(s) in these cells. This may be a major factor in the failure of the immune response to expand after HCV infection, leading to persistence. Nevertheless, it may be possible to overcome this defect by autologous transfusion of HCV antigen-loaded, mature dendritic cells and the purpose of this review is to highlight the need and general approaches for developing dendritic cell-based immunotherapy for HCV infection.

show abstract

Long-Term Histologic Improvement and Loss of Detectable Intrahepatic HCV RNA in Patients with Chronic Hepatitis C and Sustained Response to Interferon-α Therapy

Cited by 538 publications

References 0 publications

Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C

Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C

Savremena terapija hroničnog hepatitisa C: efikasnost i mogućnost predviđanja terapijskog odgovora

Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus

Contact Info

Product

Resources

About